NCT00165672

A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease

A Clinical Pharmacology Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 26 (actual)
• Sponsor: Eisai Inc. · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

To investigate esophageal reflux condition in patients with non-erosive gastroesophageal reflux disease by assessing with a 24-hour esophageal pH monitoring or effects of a 4-week treatment with 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)).

Conditions

• Non-erosive Gastroesophageal Reflux Disease

Interventions

Type	Name	Description
DRUG	RABEPRAZOLE SODIUM	rabeprazole sodium 5 mg: once daily orally for 4 weeks
DRUG	RABEPRAZOLE SODIUM	rabeprazole sodium 10 mg: once daily orally for 4 weeks

Timeline

• Start date: 2005-05-01
• Primary completion: 2005-10-01
• Completion: 2005-10-01
• First posted: 2005-09-14
• Last updated: 2011-10-05
• Results posted: 2011-10-05

Locations

13 sites across 1 country: Japan